{"product_id":"infectious-disease-management-in-animal-shelters","title":"Infectious Disease Management In Animal Shelters","description":"\u003ch2\u003eInfectious Disease Management In Animal Shelters\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eProfessional Veterinary E-Book - Instant PDF Download\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eComprehensive veterinary reference covering infectious disease management in animal shelters. This digital edition provides in-depth coverage suitable for veterinarians, veterinary students, technicians, and animal health professionals.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eKey Features:\u003c\/strong\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eInstant digital download after purchase\u003c\/li\u003e\n\u003cli\u003eHigh-quality PDF format - works on all devices\u003c\/li\u003e\n\u003cli\u003eFully searchable text for quick clinical reference\u003c\/li\u003e\n\u003cli\u003ePrintable pages for study and practice use\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003eCategory:\u003c\/strong\u003e Clinical Sciences\u003c\/p\u003e\u003cp\u003e\u003cem\u003ePublished by Global Vet and Co Ltd.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003ch3\u003eTable of Contents\u003c\/h3\u003e\n\u003cdiv class=\"gvc-locked-preview\"\u003e\n  \u003cdiv class=\"gvc-locked-icon\"\u003e🔒\u003c\/div\u003e\n  \u003ch3\u003eSample Preview\u003c\/h3\u003e\n  \u003cp\u003eThe full PDF is available after purchase. Instant download. Lifetime access. Read on any device.\u003c\/p\u003e\n  \u003cp class=\"gvc-locked-meta\"\u003eTrusted by 4,000+ veterinary professionals worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cul\u003e\n  \u003cli\u003eReferences (p.8)\u003c\/li\u003e\n  \u003cli\u003eContents (p.9)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.19)\u003c\/li\u003e\n  \u003cli\u003e2 Chemical Composition (p.22)\u003c\/li\u003e\n  \u003cli\u003e3 Turmeric Consumption (p.22)\u003c\/li\u003e\n  \u003cli\u003e4 Pharmacokinetics (p.22)\u003c\/li\u003e\n  \u003cli\u003e5 Mechanism of Action (p.23)\u003c\/li\u003e\n  \u003cli\u003e6 Digestive System (p.24)\u003c\/li\u003e\n  \u003cli\u003e7 Common Cold and Infections (p.26)\u003c\/li\u003e\n  \u003cli\u003e8 Osteoarthritis (OA, Degenerative Joint Disease) (p.26)\u003c\/li\u003e\n  \u003cli\u003e9 Pain (p.28)\u003c\/li\u003e\n  \u003cli\u003e10 Sports Medicine (p.29)\u003c\/li\u003e\n  \u003cli\u003e11 CNS Effects (p.30)\u003c\/li\u003e\n  \u003cli\u003e12 Diabetes (p.30)\u003c\/li\u003e\n  \u003cli\u003e13 Metabolic Syndrome (p.31)\u003c\/li\u003e\n  \u003cli\u003e14 Retinopathies (p.32)\u003c\/li\u003e\n  \u003cli\u003e15 Allergy (p.32)\u003c\/li\u003e\n  \u003cli\u003e16 Psoriasis (p.33)\u003c\/li\u003e\n  \u003cli\u003e17 Kidney Stones (p.33)\u003c\/li\u003e\n  \u003cli\u003e18 Cancer (p.33)\u003c\/li\u003e\n  \u003cli\u003e19 Translation from Population Epidemiology and Clinic to Bench (p.34)\u003c\/li\u003e\n  \u003cli\u003e20 Translation: Preclinical to Clinic (p.34)\u003c\/li\u003e\n  \u003cli\u003e21 Gaps and Opportunities (p.34)\u003c\/li\u003e\n  \u003cli\u003e22 Concluding Remarks and Future Directions (p.35)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.36)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.40)\u003c\/li\u003e\n  \u003cli\u003e2 Phytoconstituents (p.41)\u003c\/li\u003e\n  \u003cli\u003e3 Uses of Fenugreek (p.42)\u003c\/li\u003e\n  \u003cli\u003e4 Fenugreek in Animal, Poultry, and Fish Feeds (p.46)\u003c\/li\u003e\n  \u003cli\u003e5 Toxicology and Safety Profile (p.47)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.47)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.47)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.51)\u003c\/li\u003e\n  \u003cli\u003e2 Extracts of Neem (p.52)\u003c\/li\u003e\n  \u003cli\u003e3 Phytoconstituents (p.53)\u003c\/li\u003e\n  \u003cli\u003e4 Medicinal Uses (p.53)\u003c\/li\u003e\n  \u003cli\u003e5 Neem as Livestock Feed (p.56)\u003c\/li\u003e\n  \u003cli\u003e6 Neem as Nutraceutical (p.58)\u003c\/li\u003e\n  \u003cli\u003e7 Safety (p.59)\u003c\/li\u003e\n  \u003cli\u003e8 Toxicity (p.60)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.61)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.61)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.65)\u003c\/li\u003e\n  \u003cli\u003e2 Phytochemical Composition of Ginger (p.66)\u003c\/li\u003e\n  \u003cli\u003e3 Pharmacological Profile of Ginger (p.66)\u003c\/li\u003e\n  \u003cli\u003e4 Veterinary Use of Ginger (p.76)\u003c\/li\u003e\n  \u003cli\u003e5 Safety Profile of Ginger (p.77)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.78)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.78)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.85)\u003c\/li\u003e\n  \u003cli\u003e2 Pharmacokinetics and Pharmacodynamics (p.86)\u003c\/li\u003e\n  \u003cli\u003e3 Pharmacological and Therapeutic Potential of BBR (p.87)\u003c\/li\u003e\n  \u003cli\u003e4 Safety and Toxicity of BBR (p.92)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.92)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.93)\u003c\/li\u003e\n  \u003cli\u003e1 High-Altitude Environment (p.96)\u003c\/li\u003e\n  \u003cli\u003e2 Constraints and Prospects of Poultry Production at High-Altitude Region (p.97)\u003c\/li\u003e\n  \u003cli\u003e3 Important Diseases and Clinical Conditions of Poultry at High Altitude (p.97)\u003c\/li\u003e\n  \u003cli\u003e4 Nonconventional Sources for Poultry Feeding at High-Altitude Cold Desert (p.97)\u003c\/li\u003e\n  \u003cli\u003e5 Sea Buckthorn as a Source of Phytomolecules and Their Therapeutic Value (p.97)\u003c\/li\u003e\n  \u003cli\u003e6 Apricot as Source of Various Phytomolecules and Their Therapeutic Value (p.98)\u003c\/li\u003e\n  \u003cli\u003e7 Mechanism of Therapeutic Value of Sea Buckthorn- and Apricot-Based Nutraceuticals (p.100)\u003c\/li\u003e\n  \u003cli\u003e8 Available Sea Buckthorn and Apricot Plant-Based Feed Formulation (p.101)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.101)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.102)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.104)\u003c\/li\u003e\n  \u003cli\u003e2 Geographical Location (p.105)\u003c\/li\u003e\n  \u003cli\u003e3 Taxonomical Classification (p.105)\u003c\/li\u003e\n  \u003cli\u003e4 Chemical Constituents of NS (p.105)\u003c\/li\u003e\n  \u003cli\u003e5 Pharmacological Studies (p.106)\u003c\/li\u003e\n  \u003cli\u003e6 Toxicological Properties (p.111)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.111)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.111)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.115)\u003c\/li\u003e\n  \u003cli\u003e2 Chemical Constituents in Babool (p.115)\u003c\/li\u003e\n  \u003cli\u003e3 Nutritional Value of Babool (p.116)\u003c\/li\u003e\n  \u003cli\u003e4 Pharmacotherapeutic Effects (p.116)\u003c\/li\u003e\n  \u003cli\u003e5 Toxicity and Safety (p.120)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.120)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.120)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.124)\u003c\/li\u003e\n  \u003cli\u003e2 Metabolism of Glucosinolates (p.125)\u003c\/li\u003e\n  \u003cli\u003e3 Important Glucosinolates (p.125)\u003c\/li\u003e\n  \u003cli\u003e4 Effects of Glucosinolates (p.126)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.129)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.129)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.131)\u003c\/li\u003e\n  \u003cli\u003e2 Cannabis sativa L.: Food, Herbal Medicine, Pharmaceutical, and Nutraceutical (p.132)\u003c\/li\u003e\n  \u003cli\u003e3 Modern History of Cannabinoid Pharmacology (p.135)\u003c\/li\u003e\n  \u003cli\u003e4 Endocannabinoid (eCB) Chemistry (p.135)\u003c\/li\u003e\n  \u003cli\u003e5 Cannabis sativa Chemistry (p.143)\u003c\/li\u003e\n  \u003cli\u003e6 Animal Studies and Veterinary Clinical Trials (p.150)\u003c\/li\u003e\n  \u003cli\u003e7 Guidance on Veterinary Cannabis Products in the US Market (p.153)\u003c\/li\u003e\n  \u003cli\u003e8 Current Good Manufacturing Practices (cGMP) (p.159)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.160)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.160)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.166)\u003c\/li\u003e\n  \u003cli\u003e2 Essential Oils (p.171)\u003c\/li\u003e\n  \u003cli\u003e3 Essential Oils as Modifiers of Rumen Fermentation, Immune System, and Lactation (p.177)\u003c\/li\u003e\n  \u003cli\u003e4 Safety of Essential Oils (p.177)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.177)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.177)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.183)\u003c\/li\u003e\n  \u003cli\u003e2 Omega Fatty Acids (p.183)\u003c\/li\u003e\n  \u003cli\u003e3 Omega Fatty Acids as Nutraceuticals in Veterinary Medicine (p.184)\u003c\/li\u003e\n  \u003cli\u003e4 Potential Adverse Effects of Omega Fatty Acids in Dogs and Cats (p.191)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.191)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.191)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.194)\u003c\/li\u003e\n  \u003cli\u003e2 Phytochemicals (PCs) (p.195)\u003c\/li\u003e\n  \u003cli\u003e3 Classification of Nutraceuticals (p.200)\u003c\/li\u003e\n  \u003cli\u003e4 Significance of Polyphenols in Flora and Fauna and Human Health (p.200)\u003c\/li\u003e\n  \u003cli\u003e5 Polyphenols and Flavonoids in Human Medicine (p.203)\u003c\/li\u003e\n  \u003cli\u003e6 Polyphenols and Flavonoids in Veterinary Medicine (p.204)\u003c\/li\u003e\n  \u003cli\u003e7 Potential Use of Polyphenols and Flavonoid-Rich Plants in Animal Feeding (p.206)\u003c\/li\u003e\n  \u003cli\u003e8 Toxicity of Polyphenols and Flavonoids (p.207)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.207)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.208)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.212)\u003c\/li\u003e\n  \u003cli\u003e2 Biomarkers of Oxidative Stress (p.213)\u003c\/li\u003e\n  \u003cli\u003e3 Oxidative Stress and Neurodegeneration (p.213)\u003c\/li\u003e\n  \u003cli\u003e4 Oxidative Stress and Antioxidants in Non-neurodegenerative Diseases (p.214)\u003c\/li\u003e\n  \u003cli\u003e5 Antioxidant systems (p.214)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.217)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.217)\u003c\/li\u003e\n  \u003cli\u003e1 Prologue (p.221)\u003c\/li\u003e\n  \u003cli\u003e2 Introduction (p.221)\u003c\/li\u003e\n  \u003cli\u003e3 Relevant Biological Actions (p.224)\u003c\/li\u003e\n  \u003cli\u003e4 Pharmacological Aspects: Pharmacodynamics and Pharmacokinetics (p.228)\u003c\/li\u003e\n  \u003cli\u003e5 Adverse Effects (p.230)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.230)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.230)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.233)\u003c\/li\u003e\n  \u003cli\u003e2 Eggs and Eggshell Waste (p.233)\u003c\/li\u003e\n  \u003cli\u003e3 Structure of Eggshells and Membranes (p.233)\u003c\/li\u003e\n  \u003cli\u003e4 Eggshell Membranes (p.234)\u003c\/li\u003e\n  \u003cli\u003e5 Separation Methods of ESM (p.234)\u003c\/li\u003e\n  \u003cli\u003e6 Components of ESM (p.235)\u003c\/li\u003e\n  \u003cli\u003e7 Efficacy (in Humans) for Treating Joint Inflammation (p.235)\u003c\/li\u003e\n  \u003cli\u003e8 Efficacy (in Animals) for Treating Joint Inflammation and Modes of Action (p.235)\u003c\/li\u003e\n  \u003cli\u003e9 ESM as an Alternative to Antibiotics for Growth Promotion in Production Animals (p.236)\u003c\/li\u003e\n  \u003cli\u003e10 Nutritional Effects of Eggshell Membrane Supplements on Chicken Performance and Immunity (p.237)\u003c\/li\u003e\n  \u003cli\u003e11 Other Veterinary Uses of ESM (p.237)\u003c\/li\u003e\n  \u003cli\u003e12 Conclusion Remarks and Future Directions (p.237)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.238)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.240)\u003c\/li\u003e\n  \u003cli\u003e2 Characteristics of OVTF and LF (p.241)\u003c\/li\u003e\n  \u003cli\u003e3 OVTF and LF Receptors (p.241)\u003c\/li\u003e\n  \u003cli\u003e4 Genes of OVTF and LF (p.241)\u003c\/li\u003e\n  \u003cli\u003e5 Bioavailability of OVTF and LF (p.242)\u003c\/li\u003e\n  \u003cli\u003e6 Functional Properties of OVTF and LF (p.243)\u003c\/li\u003e\n  \u003cli\u003e7 Antibacterial Activity (p.243)\u003c\/li\u003e\n  \u003cli\u003e8 Antifungal Activity (p.244)\u003c\/li\u003e\n  \u003cli\u003e9 Antiparasitic Activity (p.244)\u003c\/li\u003e\n  \u003cli\u003e10 Antiviral Activity (p.244)\u003c\/li\u003e\n  \u003cli\u003e11 Concluding Remarks and Future Directions (p.246)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.246)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.249)\u003c\/li\u003e\n  \u003cli\u003e2 The Immune Response (p.249)\u003c\/li\u003e\n  \u003cli\u003e3 Veterinary Vaccines for Active Immunity (p.249)\u003c\/li\u003e\n  \u003cli\u003e4 Passive Immunity (p.250)\u003c\/li\u003e\n  \u003cli\u003e5 Antibodies (p.250)\u003c\/li\u003e\n  \u003cli\u003e6 Antibody Classes (p.250)\u003c\/li\u003e\n  \u003cli\u003e7 Antibody-Antigen Interactions (p.251)\u003c\/li\u003e\n  \u003cli\u003e8 Colostrum and Passive Immunity (p.251)\u003c\/li\u003e\n  \u003cli\u003e9 Colostrum Programs (p.253)\u003c\/li\u003e\n  \u003cli\u003e10 Vaccination of Newborn Animals While Receiving Colostrum (p.254)\u003c\/li\u003e\n  \u003cli\u003e11 Antibody Products (p.254)\u003c\/li\u003e\n  \u003cli\u003e12 Passive Immunity by Egg Antibodies (p.255)\u003c\/li\u003e\n  \u003cli\u003e13 Eggs as a Natural Source of Immunoregulatory Factors (p.255)\u003c\/li\u003e\n  \u003cli\u003e14 Monoclonal Antibodies in Veterinary Use (p.257)\u003c\/li\u003e\n  \u003cli\u003e15 Concluding Remarks and Future Directions (p.258)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.259)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.263)\u003c\/li\u003e\n  \u003cli\u003e2 Gastrointestinal Microbiota and Microbiome (p.263)\u003c\/li\u003e\n  \u003cli\u003e3 Classes of Alternatives to Antimicrobial Growth Promoters (p.268)\u003c\/li\u003e\n  \u003cli\u003e4 Probiotics (p.273)\u003c\/li\u003e\n  \u003cli\u003e5 Synbiotics (p.281)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.282)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.283)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.288)\u003c\/li\u003e\n  \u003cli\u003e2 Synbiotics for Animals (p.289)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.298)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.299)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.303)\u003c\/li\u003e\n  \u003cli\u003e2 Feed Enzymes and Gastrointestinal Microbiota (p.305)\u003c\/li\u003e\n  \u003cli\u003e3 Mode of Action for Enzymes (p.306)\u003c\/li\u003e\n  \u003cli\u003e4 Dietary Substrates and Enzyme Types (p.307)\u003c\/li\u003e\n  \u003cli\u003e5 Main Enzymes (p.308)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.312)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.312)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.314)\u003c\/li\u003e\n  \u003cli\u003e2 Impact of Phasing Out Animal Growth Promoters (p.316)\u003c\/li\u003e\n  \u003cli\u003e3 Biosecurity (p.318)\u003c\/li\u003e\n  \u003cli\u003e4 Reducing Antibiotic Use (p.322)\u003c\/li\u003e\n  \u003cli\u003e5 Gastrointestinal Microflora (p.324)\u003c\/li\u003e\n  \u003cli\u003e6 Antibacterial Alternatives in Animal Health (p.326)\u003c\/li\u003e\n  \u003cli\u003e7 Regulations Concerning Feed Additives in the European Union (p.336)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.338)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.343)\u003c\/li\u003e\n  \u003cli\u003e2 Classification of Animal Feed Additives (p.344)\u003c\/li\u003e\n  \u003cli\u003e3 Quality Standards for Animal Feed Additive Industry (p.354)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.358)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.362)\u003c\/li\u003e\n  \u003cli\u003e2 Pathophysiology of OA (p.363)\u003c\/li\u003e\n  \u003cli\u003e3 Diagnosis of OA (p.364)\u003c\/li\u003e\n  \u003cli\u003e4 Nutraceuticals in the Management of OA (p.365)\u003c\/li\u003e\n  \u003cli\u003e5 Novel Nutraceuticals (p.372)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.374)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.374)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.379)\u003c\/li\u003e\n  \u003cli\u003e2 Signs of Aging (p.380)\u003c\/li\u003e\n  \u003cli\u003e3 Antiaging Nutraceuticals and Functional Foods (p.382)\u003c\/li\u003e\n  \u003cli\u003e4 Concluding Remarks and Future Directions (p.386)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.386)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.389)\u003c\/li\u003e\n  \u003cli\u003e2 Canine Cognitive Dysfunction (p.390)\u003c\/li\u003e\n  \u003cli\u003e3 Pathophysiology (p.390)\u003c\/li\u003e\n  \u003cli\u003e4 Diagnosis of Cognition Dysfunction (p.391)\u003c\/li\u003e\n  \u003cli\u003e5 Prevention and Treatment of Cognitive Dysfunction (p.391)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.404)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.404)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.412)\u003c\/li\u003e\n  \u003cli\u003e2 Neurotransmitters, Neuropeptides, and HPA Axis in Stress and Anxiety (p.413)\u003c\/li\u003e\n  \u003cli\u003e3 Dietary Supplements in Calming (p.415)\u003c\/li\u003e\n  \u003cli\u003e4 Herbal Extracts in Calming (p.416)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.417)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.418)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.421)\u003c\/li\u003e\n  \u003cli\u003e2 Nutraceuticals Modulate Genetic Expression (p.422)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceuticals that Forestall the Development of Cardiac Dysfunction (p.422)\u003c\/li\u003e\n  \u003cli\u003e4 Soy (p.426)\u003c\/li\u003e\n  \u003cli\u003e5 Cardiac Biomarkers in Animals (p.426)\u003c\/li\u003e\n  \u003cli\u003e6 Cardiac Issues in Animals (p.426)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.427)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.428)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.440)\u003c\/li\u003e\n  \u003cli\u003e2 Pathophysiology of Periodontal Diseases (p.441)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceuticals in Periodontal Diseases (p.443)\u003c\/li\u003e\n  \u003cli\u003e4 Concluding Remarks and Future Directions (p.455)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.455)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.460)\u003c\/li\u003e\n  \u003cli\u003e2 Phytochemicals for Gastrointestinal Conditions (p.461)\u003c\/li\u003e\n  \u003cli\u003e3 Dietary Lipids and Fat-Soluble Vitamins for Gastrointestinal Conditions (p.464)\u003c\/li\u003e\n  \u003cli\u003e4 Dietary Peptides and Amino Acids for Gastrointestinal Conditions (p.465)\u003c\/li\u003e\n  \u003cli\u003e5 Probiotics, Prebiotics, and Synbiotics (p.466)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.468)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.469)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.473)\u003c\/li\u003e\n  \u003cli\u003e2 Nutraceutical in Female Reproductive Abnormalities (p.473)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceutical in Male Reproductive Abnormalities\/Diseases (p.478)\u003c\/li\u003e\n  \u003cli\u003e4 Concluding Remarks and Future Directions (p.479)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.479)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.481)\u003c\/li\u003e\n  \u003cli\u003e2 Oxidative Stress in Dairy Cows (p.482)\u003c\/li\u003e\n  \u003cli\u003e3 Melatonin and Seasonal Breeders (p.483)\u003c\/li\u003e\n  \u003cli\u003e4 Herbs (p.483)\u003c\/li\u003e\n  \u003cli\u003e5 Dietary Lipids (p.485)\u003c\/li\u003e\n  \u003cli\u003e6 Carnitine (p.488)\u003c\/li\u003e\n  \u003cli\u003e7 Nutraceuticals in Assisted Reproduction (p.491)\u003c\/li\u003e\n  \u003cli\u003e8 Coconut (Cocos nucifera L.) (p.492)\u003c\/li\u003e\n  \u003cli\u003e9 Quercetin (p.493)\u003c\/li\u003e\n  \u003cli\u003e10 Vitamins and Selenium (Se) (p.494)\u003c\/li\u003e\n  \u003cli\u003e11 Ancillary Nutraceuticals (p.495)\u003c\/li\u003e\n  \u003cli\u003e12 Urinary Diseases (p.495)\u003c\/li\u003e\n  \u003cli\u003e13 Nutraceutical Recipes and Candidate Nutraceuticals (p.498)\u003c\/li\u003e\n  \u003cli\u003e14 Probiotics (p.499)\u003c\/li\u003e\n  \u003cli\u003e15 Ethnoveterinary Medicine (p.499)\u003c\/li\u003e\n  \u003cli\u003e16 Concluding Remarks and Future Directions (p.502)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.502)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.507)\u003c\/li\u003e\n  \u003cli\u003e2 Curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (p.507)\u003c\/li\u003e\n  \u003cli\u003e3 Lagenaria siceraria (Bottle Gourd) (p.508)\u003c\/li\u003e\n  \u003cli\u003e4 Trigonella foenum-graecum (Fenugreek) (p.509)\u003c\/li\u003e\n  \u003cli\u003e5 Emblica officinalis (syn. Phyllanthus emblica; Indian Gooseberry) (p.509)\u003c\/li\u003e\n  \u003cli\u003e6 Murraya koenigii (Curry Tree) (p.509)\u003c\/li\u003e\n  \u003cli\u003e7 Vigna sp. (Black Gram, Black Lentil, Cow Pea, Black-Eyed Pea, Adzuki Bean, Mung Bean) (p.509)\u003c\/li\u003e\n  \u003cli\u003e8 Camellia sinensis (Tea) (p.510)\u003c\/li\u003e\n  \u003cli\u003e9 Hibiscus sabdariffa (p.510)\u003c\/li\u003e\n  \u003cli\u003e10 Hypericum perforatum (St. John´s Wort) (p.511)\u003c\/li\u003e\n  \u003cli\u003e11 Persea americana (Avocado) (p.511)\u003c\/li\u003e\n  \u003cli\u003e12 Capsicum annuum (Capsicum) (p.511)\u003c\/li\u003e\n  \u003cli\u003e13 Rosmarinus officinalis (Rosemary) (p.512)\u003c\/li\u003e\n  \u003cli\u003e14 Concluding Remarks and Future Directions (p.512)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.512)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.515)\u003c\/li\u003e\n  \u003cli\u003e2 Pathophysiology of Diabetes Mellitus (p.516)\u003c\/li\u003e\n  \u003cli\u003e3 Experimental Diabetes Models (p.516)\u003c\/li\u003e\n  \u003cli\u003e4 Diabetic Monitoring (p.517)\u003c\/li\u003e\n  \u003cli\u003e5 Prevention and Management of Diabetes in Animals (p.517)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.526)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.526)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.532)\u003c\/li\u003e\n  \u003cli\u003e2 Pathophysiology of Wound and Wound Healing (p.533)\u003c\/li\u003e\n  \u003cli\u003e3 Wound Healing: A New Multi-spectrum Twenty-First-Century Perspective (p.534)\u003c\/li\u003e\n  \u003cli\u003e4 Models of Wound and Wound Healing (p.534)\u003c\/li\u003e\n  \u003cli\u003e5 Formulations of Nutraceuticals and Their Delivery Systems for Wound Healing (p.537)\u003c\/li\u003e\n  \u003cli\u003e6 Nutraceuticals\/Phytochemical Extracts from C. odorata for Wound Healing (p.538)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.547)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.548)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.554)\u003c\/li\u003e\n  \u003cli\u003e2 Nutraceuticals in Dermatitis (p.554)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceuticals in Otitis Externa (p.555)\u003c\/li\u003e\n  \u003cli\u003e4 Nutraceuticals in Infection-Associated Dermatitis (p.555)\u003c\/li\u003e\n  \u003cli\u003e5 Nutraceuticals in Allergic\/Atopic Dermatitis (p.557)\u003c\/li\u003e\n  \u003cli\u003e6 Nutraceuticals in Skin (Cutaneous) Tumors (Neoplasms) (p.557)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.558)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.559)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.560)\u003c\/li\u003e\n  \u003cli\u003e2 Alternative Therapies (p.561)\u003c\/li\u003e\n  \u003cli\u003e3 Dry Cow Treatments (p.566)\u003c\/li\u003e\n  \u003cli\u003e4 Homeopathy (p.567)\u003c\/li\u003e\n  \u003cli\u003e5 Probiotics, Bacteriocins, and Bacteriophages (p.568)\u003c\/li\u003e\n  \u003cli\u003e6 Bacteriophages and Their Products (p.571)\u003c\/li\u003e\n  \u003cli\u003e7 Vitamin and Mineral Supplementation (p.571)\u003c\/li\u003e\n  \u003cli\u003e8 Teat Dips (p.572)\u003c\/li\u003e\n  \u003cli\u003e9 Immunotherapy (p.573)\u003c\/li\u003e\n  \u003cli\u003e10 Concluding Remarks and Future Directions (p.573)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.573)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.577)\u003c\/li\u003e\n  \u003cli\u003e2 Nutraceuticals in Regulation of Immune System (p.578)\u003c\/li\u003e\n  \u003cli\u003e3 Anti-inflammatory Effects of Nutraceutical (p.578)\u003c\/li\u003e\n  \u003cli\u003e4 Nutraceuticals in Degenerative and Metabolic Diseases (p.579)\u003c\/li\u003e\n  \u003cli\u003e5 Nutraceuticals in Hypersensitivity (Allergic) Disorders and Other Inflammatory Diseases (p.580)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.581)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.581)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.582)\u003c\/li\u003e\n  \u003cli\u003e2 Plant-Derived Immunomodulators (p.583)\u003c\/li\u003e\n  \u003cli\u003e3 Food-Derived Immunomodulators (p.585)\u003c\/li\u003e\n  \u003cli\u003e4 Clinical Applications of Food-Derived Nutraceuticals (p.589)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.589)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.589)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.592)\u003c\/li\u003e\n  \u003cli\u003e2 Anticancer Activities of Nutraceuticals (p.593)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.595)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.595)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.599)\u003c\/li\u003e\n  \u003cli\u003e2 Vitamin C in Combination with Individual Natural Compounds (p.600)\u003c\/li\u003e\n  \u003cli\u003e3 Vitamin C in Combination with Multiple Nutrients (p.602)\u003c\/li\u003e\n  \u003cli\u003e4 Green Tea Polyphenol (EGCG) in Combination with Other Natural Compounds (p.603)\u003c\/li\u003e\n  \u003cli\u003e5 EGCG in Combinations with Multiple Nutrients (p.604)\u003c\/li\u003e\n  \u003cli\u003e6 Novel Approach to Cancer Through Synergistic Combination of Vitamin C with EGCG and Other Nutrients (p.605)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.608)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.609)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.613)\u003c\/li\u003e\n  \u003cli\u003e2 Nutraceuticals for Control of Ticks, Fleas, and Other Ectoparasites (p.614)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.619)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.619)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.623)\u003c\/li\u003e\n  \u003cli\u003e2 Major Classes of Nutraceuticals Used in Cattle (p.624)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.630)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.631)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.635)\u003c\/li\u003e\n  \u003cli\u003e2 Regulatory Scenario (p.636)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceuticals (p.636)\u003c\/li\u003e\n  \u003cli\u003e4 Nutraceuticals as Joint Supplements (p.637)\u003c\/li\u003e\n  \u003cli\u003e5 Nutraceuticals as Performance Boosters (p.638)\u003c\/li\u003e\n  \u003cli\u003e6 The Use of Nutritional Supplements in Dressage and Eventing Horses (p.640)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.641)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.641)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.642)\u003c\/li\u003e\n  \u003cli\u003e2 Active Nutraceuticals (p.643)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.645)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.646)\u003c\/li\u003e\n  \u003cli\u003e2 Probiotics (p.647)\u003c\/li\u003e\n  \u003cli\u003e3 Prebiotics (p.648)\u003c\/li\u003e\n  \u003cli\u003e4 Synbiotics (p.649)\u003c\/li\u003e\n  \u003cli\u003e5 Exogenous Enzymes (p.650)\u003c\/li\u003e\n  \u003cli\u003e6 Organic Acids (p.651)\u003c\/li\u003e\n  \u003cli\u003e7 Polyunsaturated Fatty Acids (p.652)\u003c\/li\u003e\n  \u003cli\u003e8 Phytobiotics (p.653)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.654)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.654)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.660)\u003c\/li\u003e\n  \u003cli\u003e2 Toxic Actions of Nutraceuticals (p.661)\u003c\/li\u003e\n  \u003cli\u003e3 Safety and Toxicity Studies with Animal Models: Foundations, Problems, and Alternatives (p.662)\u003c\/li\u003e\n  \u003cli\u003e4 Unresolved Issues (p.665)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.666)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.669)\u003c\/li\u003e\n  \u003cli\u003e2 Drosophila melanogaster as a Model Organism (p.670)\u003c\/li\u003e\n  \u003cli\u003e3 Utility of Drosophila in Examining the Anticancer Potential of Nutraceuticals (p.670)\u003c\/li\u003e\n  \u003cli\u003e4 Utility of Drosophila in Examining the Efficacy of Nutraceuticals Against Aging (p.671)\u003c\/li\u003e\n  \u003cli\u003e5 Utility of Drosophila in Examining the Efficacy of Nutraceuticals Against Neurodegenerative Diseases (p.671)\u003c\/li\u003e\n  \u003cli\u003e6 Utility of Drosophila in the Toxicity Evaluation of Nutraceuticals (p.672)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.673)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.674)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.677)\u003c\/li\u003e\n  \u003cli\u003e2 Complexities in Food and Nutraceutical Biomarkers (p.678)\u003c\/li\u003e\n  \u003cli\u003e3 Analysis of Antioxidant Activity (p.678)\u003c\/li\u003e\n  \u003cli\u003e4 Analysis of Anti-inflammatory Activity (p.679)\u003c\/li\u003e\n  \u003cli\u003e5 Analgesic Activity (p.679)\u003c\/li\u003e\n  \u003cli\u003e6 Biomarkers of Foods and Nutraceuticals (p.679)\u003c\/li\u003e\n  \u003cli\u003e7 Biomarkers of Polyphenols and Related Compounds: A Pharmacokinetic Perspective (p.679)\u003c\/li\u003e\n  \u003cli\u003e8 Biomarkers of Toxicity and Safety Evaluation of Foods and Nutraceuticals (p.688)\u003c\/li\u003e\n  \u003cli\u003e9 Biomarkers of Nutraceuticals with Toxic Potential (p.689)\u003c\/li\u003e\n  \u003cli\u003e10 Concluding Remarks and Future Directions (p.689)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.689)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.695)\u003c\/li\u003e\n  \u003cli\u003e2 Hepatotoxicity (p.695)\u003c\/li\u003e\n  \u003cli\u003e3 Known Drug-Drug Interactions of Nutraceuticals (p.696)\u003c\/li\u003e\n  \u003cli\u003e4 Cardiovascular Effects (p.696)\u003c\/li\u003e\n  \u003cli\u003e5 Allergic and Skin Effects Not Associated with Hepatotoxicity (p.696)\u003c\/li\u003e\n  \u003cli\u003e6 Adverse Effects on the Coagulation System (p.701)\u003c\/li\u003e\n  \u003cli\u003e7 Adverse Effects on the Central Nervous System (p.702)\u003c\/li\u003e\n  \u003cli\u003e8 Effects on the Musculoskeletal System (p.702)\u003c\/li\u003e\n  \u003cli\u003e9 Endocrine and Reproductive System Effects (p.702)\u003c\/li\u003e\n  \u003cli\u003e10 Concluding Remarks and Future Directions (p.702)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.702)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.713)\u003c\/li\u003e\n  \u003cli\u003e2 Nutriproteomics (p.714)\u003c\/li\u003e\n  \u003cli\u003e3 Foodomics (p.715)\u003c\/li\u003e\n  \u003cli\u003e4 Concluding Remarks and Future Directions (p.716)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.717)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.719)\u003c\/li\u003e\n  \u003cli\u003e2 Advanced Matrices for Drug Vehiculation: Chemical-Physical Aspects of the Nanomaterials for Molecular Delivery (p.720)\u003c\/li\u003e\n  \u003cli\u003e3 Vesicles and Related Aggregates (p.721)\u003c\/li\u003e\n  \u003cli\u003e4 Carbon Nanotubes (p.722)\u003c\/li\u003e\n  \u003cli\u003e5 Nanomaterials as Cargos of Biological Molecules: Potential Usage in Advanced Therapeutic Strategies (p.723)\u003c\/li\u003e\n  \u003cli\u003e6 Liposomes (p.724)\u003c\/li\u003e\n  \u003cli\u003e7 Cat-Anionic Vesicles (p.724)\u003c\/li\u003e\n  \u003cli\u003e8 Nanotubes (p.725)\u003c\/li\u003e\n  \u003cli\u003e9 Concluding Remarks and Future Directions (p.726)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.727)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.730)\u003c\/li\u003e\n  \u003cli\u003e2 Nanosupplement Delivery (p.731)\u003c\/li\u003e\n  \u003cli\u003e3 Animal Production (p.733)\u003c\/li\u003e\n  \u003cli\u003e4 Anti-inflammatory Activity (p.740)\u003c\/li\u003e\n  \u003cli\u003e5 Immunity (p.740)\u003c\/li\u003e\n  \u003cli\u003e6 Risks and Challenges (p.742)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.742)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.742)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.746)\u003c\/li\u003e\n  \u003cli\u003e2 Factors That Affect Stability of Nutraceuticals (p.747)\u003c\/li\u003e\n  \u003cli\u003e3 Categories of Nutraceuticals and Their Stability (p.748)\u003c\/li\u003e\n  \u003cli\u003e4 Stability Testing Methods (p.751)\u003c\/li\u003e\n  \u003cli\u003e5 Regulatory Guideline Aspects Related to Nutraceutical Stability (p.753)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.754)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.754)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.757)\u003c\/li\u003e\n  \u003cli\u003e2 DSHEA (p.757)\u003c\/li\u003e\n  \u003cli\u003e3 FDA\/CVM (p.758)\u003c\/li\u003e\n  \u003cli\u003e4 AFFCO (p.759)\u003c\/li\u003e\n  \u003cli\u003e5 Claims for Probiotics (p.760)\u003c\/li\u003e\n  \u003cli\u003e6 Trade Organizations Related to Veterinary Nutraceuticals (p.760)\u003c\/li\u003e\n  \u003cli\u003e7 Legally Marketing an Animal Nutraceutical in the USA (p.761)\u003c\/li\u003e\n  \u003cli\u003e8 Regulatory Rules in Different Countries for Veterinary Nutraceuticals (p.762)\u003c\/li\u003e\n  \u003cli\u003e9 The Future of Veterinary Nutraceutical Regulations (p.763)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.763)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.765)\u003c\/li\u003e\n  \u003cli\u003e2 FDA Perspective (p.766)\u003c\/li\u003e\n  \u003cli\u003e3 Inapplicability of DSHEA to Veterinary Products (p.766)\u003c\/li\u003e\n  \u003cli\u003e4 Feed Additives (p.767)\u003c\/li\u003e\n  \u003cli\u003e5 Nutraceuticals for Pets (p.767)\u003c\/li\u003e\n  \u003cli\u003e6 Safety Concerns (p.768)\u003c\/li\u003e\n  \u003cli\u003e7 Regulations in Canada (p.768)\u003c\/li\u003e\n  \u003cli\u003e8 Included and Excluded Products (p.769)\u003c\/li\u003e\n  \u003cli\u003e9 Labeling Guidance (p.769)\u003c\/li\u003e\n  \u003cli\u003e10 Manufacturing Requirements (p.770)\u003c\/li\u003e\n  \u003cli\u003e11 Reporting of Adverse Effects (p.770)\u003c\/li\u003e\n  \u003cli\u003e12 Compliance and Enforcement (p.770)\u003c\/li\u003e\n  \u003cli\u003e13 Concluding Remarks and Future Directions (p.770)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.771)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.772)\u003c\/li\u003e\n  \u003cli\u003e2 Guidelines for the Distinction Between Feed Materials, Feed Additives, and Veterinary Medicinal Products (p.773)\u003c\/li\u003e\n  \u003cli\u003e3 Nutraceuticals as Feed Material (p.774)\u003c\/li\u003e\n  \u003cli\u003e4 Nutraceuticals as Feed Additives (p.774)\u003c\/li\u003e\n  \u003cli\u003e5 Nutraceutical Properties Claimed on Animal Feed Labels (p.778)\u003c\/li\u003e\n  \u003cli\u003e6 Nutraceuticals as Veterinary Medicinal Products (VMPs) (p.778)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.781)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.783)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.785)\u003c\/li\u003e\n  \u003cli\u003e2 Historical Background (p.786)\u003c\/li\u003e\n  \u003cli\u003e3 Contribution of Livestock Sector in GDP (p.786)\u003c\/li\u003e\n  \u003cli\u003e4 Indian Market and Animal Health Nutrition: Current Trends (p.787)\u003c\/li\u003e\n  \u003cli\u003e5 Overview of Regulations of Other Countries (p.788)\u003c\/li\u003e\n  \u003cli\u003e6 Regulations (p.789)\u003c\/li\u003e\n  \u003cli\u003e7 Regulatory Requirements for Entry in India (p.790)\u003c\/li\u003e\n  \u003cli\u003e8 Product Evaluation (p.790)\u003c\/li\u003e\n  \u003cli\u003e9 The Benefits (p.791)\u003c\/li\u003e\n  \u003cli\u003e10 The Disadvantages (p.791)\u003c\/li\u003e\n  \u003cli\u003e11 Role of Government and Public Sector Institutes (p.791)\u003c\/li\u003e\n  \u003cli\u003e12 Concluding Remarks and Future Directions (p.791)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.792)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.793)\u003c\/li\u003e\n  \u003cli\u003e2 Classification (p.794)\u003c\/li\u003e\n  \u003cli\u003e3 Uses of Chinese Native Nutraceuticals (p.794)\u003c\/li\u003e\n  \u003cli\u003e4 Regulatory Guidelines of Nutraceuticals in China (p.796)\u003c\/li\u003e\n  \u003cli\u003e5 Concluding Remarks and Future Directions (p.798)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.798)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.800)\u003c\/li\u003e\n  \u003cli\u003e2 What Is and Is Not a Therapeutic Good in Australia (p.800)\u003c\/li\u003e\n  \u003cli\u003e3 What is a Complementary Medicine in Australia? (p.802)\u003c\/li\u003e\n  \u003cli\u003e4 What Is and Is Not a Therapeutic Product in New Zealand and How Are They Regulated? (p.802)\u003c\/li\u003e\n  \u003cli\u003e5 What is a Novel Food in Australia and New Zealand (p.803)\u003c\/li\u003e\n  \u003cli\u003e6 Concluding Remarks and Future Directions (p.804)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.804)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.805)\u003c\/li\u003e\n  \u003cli\u003e2 Applications Relating to Feed Hygiene Regulation (p.806)\u003c\/li\u003e\n  \u003cli\u003e3 Applications Relating to the Regulation on Placing on the Market and Feed Use (p.807)\u003c\/li\u003e\n  \u003cli\u003e4 Applications Relating to the Communiqué on Undesirable Substances in Animal Feed (p.807)\u003c\/li\u003e\n  \u003cli\u003e5 Applications Relating to the Regulation on the Official Control of Feed and Food (p.807)\u003c\/li\u003e\n  \u003cli\u003e6 Applications Relating to the Regulation on Feed Additives for Use in Animal Nutrition (p.807)\u003c\/li\u003e\n  \u003cli\u003e7 Concluding Remarks and Future Directions (p.812)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.812)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.813)\u003c\/li\u003e\n  \u003cli\u003e2 Regulation of Nutraceuticals (p.814)\u003c\/li\u003e\n  \u003cli\u003e3 Concluding Remarks and Future Directions (p.816)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.816)\u003c\/li\u003e\n  \u003cli\u003e1 Introduction (p.818)\u003c\/li\u003e\n  \u003cli\u003e2 Legislative Framework in South Africa (p.818)\u003c\/li\u003e\n  \u003cli\u003e3 General Control of Veterinary Nutraceuticals (p.821)\u003c\/li\u003e\n  \u003cli\u003e4 Concluding Remarks and Future Directions (p.823)\u003c\/li\u003e\n  \u003cli\u003eReferences (p.823)\u003c\/li\u003e\n  \u003cli\u003eIndex (p.824)\u003c\/li\u003e\n  \u003cli\u003e\u003cem\u003e... and 84 more chapters\u003c\/em\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e🔗 Download Link:\u003c\/strong\u003e \u003c\/p\u003e","brand":"Global Vet \u0026 Co","offers":[{"title":"Default Title","offer_id":51226937590075,"sku":null,"price":210.0,"currency_code":"HKD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0948\/3062\/5083\/files\/infectious-disease-management-in-animal-shelters_HD.png?v=1780499195","url":"https:\/\/globalvetco.com\/products\/infectious-disease-management-in-animal-shelters","provider":"Global Vet \u0026 Co Ltd","version":"1.0","type":"link"}